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Abstract. This study was conducted to investigate the clini-
copathological parameters in elderly women (aged >70 years) 
with infiltrating lobular carcinoma (ILC) of the breast and 
compare the results with those obtained from younger patients 
(aged 55-70 years). The study sample included a total of 
46 women with ILCs, 10 aged >70 and 36 aged 55-70 years. 
The parameters analysed were tumor size, histological grade 
(HG), axillary lymph node involvement, distant metastasis and 
immunohistochemical expression of estrogen, progesterone 
and androgen receptors, Ki67, p53 and B cell lymphoma 2. 
Compared to women aged 55-70 years, ILCs in women 
aged >70 years were commonly of larger size (P=0.068) and 
were more frequently HG3 (P=0.024). There were no statisti-
cally significant differences in the other parameters analysed. 
Furthermore, we were unable to determine differences in 
cancer recurrence and mortality in the two patient subgroups 
during our follow-up. In conclusion, our preliminary results, 
based on the limited number of cases included in this study, 
indicate that i) ILCs in women aged >70 years tended to be 
larger compared to those in women aged 55-70 years and were 
more frequently of grade 3; and ii) there were no significant 
differences in terms of recurrence and mortality between the 
two patient subgroups during our follow-up.
Introduction
Breast cancer is one of the most common types of cancer 
in women. Next to gender, the primary risk factor for breast 
cancer is age. Over 50% of breast cancers occur in women 
aged ≥65 years, 35% of the patients are aged >70 years and 
~10% of breast cancer patients are aged >80 years. Similarly, 
breast cancer is the most common cause of cancer-related 
mortality in women aged >65 years. For this reason, the 
American Geriatric Society recommends a screening 
mammography for women aged ≤85 years with a life expec-
tancy of ≥3 years. In addition, the life expectancy of women 
aged >70 years is 15.5 years and half of these women live 
longer; therefore, their risk may increase significantly. Of 
note, individuals aged ≥65 years represented 11.3% of the total 
population in USA in 1980 and this percentage is expected to 
increase to 20% by 2030 (1). Therefore, women aged >70 years 
constitute a group we must focus our attention on due to its 
marked social significance.
Infiltrating lobular carcinoma (ILC) is the second most 
common (5-15%) type of invasive breast cancer following 
infiltrating ductal carcinoma (IDC). It was previously demon-
strated that the incidence rate of lobular carcinoma increased 
steadily between 1977 and 1995 in women aged ≥50 years, 
whereas it remained stable in women aged <50 years (2). 
Other investigators consider that the decline in the incidence 
of ILC may be associated with the reduced use of combined 
hormone replacement therapy (3). ILC is more likely to 
present as multifocal, multicentric and bilateral disease; 
in addition, it exhibits an increasing incidence in patients 
aged >50 years and tends to be sized >2 cm, have a nuclear 
grade of 1/2, be estrogen receptor (ER)- and progesterone 
receptor (PR)-positive, human epithelial growth receptor 2 
(HER2)̸neu-negative, exhibit high CD44 expression, low 
stromal vascular endothelial growth factor receptor 2 expres-
sion, no E-cadherin expression and low laminin-5 expression, 
as compared to IDC (4-7). Other distinguishing characteris-
tics included its association with endocrine responsiveness, 
patterns of recurrence and overall prognosis (8).
A number of studies have analyzed the metastatic patterns 
of breast carcinoma and it is currently well known that ILC 
diverges significantly from IDC in terms of patterns of 
late local recurrence and sites of distant metastasis (9,10). 
Borst and Ingold (11) reported that the rates of metastasis to 
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the gastrointestinal system (4.5 vs. 0.2%), reproductive organs 
(4.5 vs. 0.8%), peritoneum-retroperitoneum (3.1 vs. 0.6%), 
adrenal glands (0.6 vs. 0%), bone marrow (21.2 vs. 14.4%) 
and lung-pleura (2.5 vs. 10.2%) were significantly different 
(P<0.05) between ILC and IDC, respectively, and were higher 
in ILC. For this reason, certain investigators recommend 
including gynecological and gastrointestinal tract evaluation 
in the follow-up of such patients. Another interesting aspect 
is that lobular breast cancer patients are more likely to have 
a father diagnosed with cancer, particularly prostate cancer.
The increased life expectancy of the female population 
is associated with increased detection of breast tumors in 
women of advanced age. In this regard, peculiarities in the 
mammary tumors of women aged >70 years, as compared to 
those of younger patients, were previously reported (12,13). 
The biological behavior of ILC has not been fully elucidated. 
Therefore, the aim of this study was to analyze the possible 
clinicopathological differences in ILC between women 
aged >70 and those aged 55-70 years.
Materials and methods
Patients. The study group included 46 women with ILC, 
10 aged >70 and 36 aged 55-70 years, recruited at the Breast 
Unit of Hospital Monte Naranco (Oviedo, Spain). The 
parameters analyzed were tumor size, histological grade 
(HG), axillary lymph node involvement, distant metastasis 
and immunohistochemical expression of ER, PR, androgen 
receptor (AR), Ki67, p53 and B cell lymphoma 2 (Bcl-2). The 
characteristics of the patients are summarized in Table I.
Immunohistochemical analysis. Monoclonal antibodies 
against ER/PR pharmDx (prediluted clones 1D5 and ER-2123 
for ER and PR) 1294 for PR, p53 (DO-7; dilution 1:100; Dako, 
Carpinteria, CA, USA), Ki67 (MIB-1; dilution 1:200; Dako), 
Bcl-2 (dilution 1:124; BioGenex, Fremont, CA, USA) and AR 
(AR441; dilution 1:75; Dako) were used in this study. The ER 
and PR were assessed according to the Allred score (14) as 
negative (scores 0-2) and positive (scores 3-8) and the threshold 
of positivity for p53 and Ki67 was 20 and 15%, respectively. 
AR was classified as positive or negative without scoring and 
Bcl-2 was classified as negative (-), weakly positive (+) and 
strongly positive (++). A total of 36 women were followed up 
over a period of 1-228 months (73.7±56.1; mean, 71 months).
Statistical analysis. SPSS software for Windows (version 20.0; 
SPSS, Inc., Chicago, IL, USA) was employed for statistical 
analysis. Continuous variables with a normal Gaussian 
distribution were expressed as means ± standard deviation, 
while non-parametric variables were expressed as median and 
range. We used the Chi-square test with Yates correction, if 
necessary, for the comparison of qualitative variables and the 
Mann-Whitney U test for continuous variables. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Association of patient age with clinicopathological param-
eters. As shown in Table I, ILC patients aged >70 years 
exhibited larger tumors, compared to those aged 55-70 years, 
with a borderline level of statistical significance (P=0.068). 
In addition, the tumors were HG3 in patients aged >70 years 
more frequently compared to those in younger patients; this 
difference was statistically significant (P=0.024). The other 
parameters analyzed, including axillary nodal status, distant 
metastasis, ER, PR and AR status, Bcl-2, p53 and Ki67, were 
not statistically significantly different between the two age 
groups. Furthermore, we were unable to identify differences 
in the incidence of disease recurrence and mortality between 
our patient subgroups during the follow-up time.
Discussion
Breast cancer becomes more prevalent with increasing 
age; its incidence may increase up to 80 years and plateaus 
between 80 and 85 years of age (15). IDC remains the most 
common histological subtype of breast cancer diagnosed 
in older patients and this type of cancer exhibits an overall 
more favorable biological profile, with a higher percentage 
of ER-positive tumors that increases with age to 91% in 
patients aged ≥85 years (16). The tumors of older patients are 
reportedly more often detected by clinical examination rather 
than imaging techniques (17). Of note, a more elderly cohort 
(age, ≥85 years) are more likely to present with metastatic 
Table I. Distribution of different clinicopathological param-






Parameters (n=10) (n=36) P-value
Size, cm   0.068
  Means±SD 2,5±1.1 2.0±1.3
  Median 2.4 1.5
  Range 1-5 0.6-6.5
N+ 3/10 11/36 NS
N+ >3 1/10 2/36 NS
M+ 2/10 2/36 NS
HG3 3/10 1/36 0.024
ER+ 10/10 36/36 NS
PR+ 9/10 20/36 NS
AR+ 10/10 33/36 NS
Bcl-2+ 10/10 35/36 NS
p53+ 2/10 3/36 NS
Ki67+ 3/10 14/36 NS
Recurrences 1/9 2/27 NS
Metastases 1/9 0/27 NS
N, axillary lymph node involvement; NS, non-significant; M, distant 
metastasis; HG, histological grade; ER, estrogen receptor; PR, proges-
terone receptor; AR, androgen receptor; Bcl-2, B-cell lymphoma 2.
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disease (9%) or an unknown stage at the time of diag-
nosis (15,17). Certain authors consider younger patients to be 
associated with a worse prognosis compared to older patients; 
however, the reported findings have been inconclusive.
Schonberg et al (18) reported that breast cancer charac-
teristics appear to be similar between patients aged ≥80 years 
and younger patients; however, patients aged ≥80 years 
receive less aggressive treatment compared to their younger 
counterparts and are more likely to succumb to breast cancer. 
Fisher et al (19) suggested that, as the life expectancy of women 
aged >70 years may be high, treatment should be based on the 
histological prognostic characteristics of the primary tumor 
rather than age alone.
As regards ILC, its incidence was not significantly different 
between women aged >70 and those aged 55-70 years (8.5 and 
8.3%, respectively), which was consistent with the findings of 
Schonberg et al (18); however, the incidence of IDC was lower 
in women aged >70 years compared to that in younger women 
(70.9 vs. 81.1%, respectively). Fisher et al (19) reported that 
lobular carcinoma exhibited a gradual increase in incidence 
with increasing age, with the highest incidence observed among 
patients aged >70 years. ILCs exhibit certain peculiarities 
compared to IDCs, particularly regarding metastatic behavior, 
as previously mentioned. However, the behavior of these breast 
tumors in elderly women (aged >70 years) has not been clearly 
determined, partly due to their lower incidence. Therefore, we 
aimed to investigate certain clinicopathological parameters and 
compare the results with those obtained from younger women 
(aged 55-70 years) with the same type of tumor. We observed 
that the ILCs of patients aged >70 years tended to be of larger 
size, with a borderline statistically significant difference, 
whereas they were more frequently HG3, with a statistically 
significant difference. There were no significant differences in 
the remaining analyzed parameters or in the incidence of recur-
rence and mortality between the two age subgroups.
As regards tumor size, our results were consistent with 
those reported by other groups, indicating that tumor size 
increases with age and the increase is more significant after 
the age of 80 years (18). We observed that the characteristics 
and the clinical and biological behavior of breast carcinomas 
in women aged >70 years differs according to their origin. 
Tumors tended to be larger, with more frequent axillary 
node involvement and distant metastases when diagnosed 
by physical examination during a routine visit; however, for 
tumors diagnosed through screening, there were no signifi-
cant differences between women aged >70 and those aged 
55-70 years (20).
Histological grade is a well known, strong predictor of 
outcome in patients with invasive breast cancer (21), in whole 
series as well as in different subgroups based on tumor size 
and lymph node stage, and it should be incorporated in breast 
cancer staging systems. Likewise, breast tumor as an entity 
in elderly women is associated with larger size, a higher 
number of metastatic lymph nodes, advanced clinical stage, 
higher HER2 positivity rate, negative ER and PR; it is also 
associated with triple-negative and HER2 subtypes (15,22). 
Cuan Martínez et al (12) reported more highly differentiated 
ductal carcinomas in the group of patients aged ≥70 years. Of 
note, Fisher et al (19) reported a negative association between 
high-grade tumors and lymphoplasmacytic reaction; however, 
the clinical value of the latter has not been clearly established, 
although it may be associated with a more favorable outcome 
only in HG3 cases (23).
Our preliminary results, based on the limited number of 
cases included in the study, indicated that i) ILCs in women 
aged >70 years tend to be larger compared to those in women 
aged 55-70 years (P=0.068) and were more frequently HG3 
(P=0.024); and ii) there were no significant differences in terms 
of recurrence and mortality between the two patient subgroups 
during our follow-up.
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